Pharmaceutical News

RSS

Genmab reports GBP 9 million net sales for Arzerra in fourth quarter 2010

Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the fourth quarter of 2010 were GBP 9 million (approximately DKK 77 million).

3 Feb 2011

AVEO receives USAN, WHO generic name approval for ficlatuzumab

AVEO Pharmaceuticals, Inc. today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name "ficlatuzumab" (pronounced fye" kla tue' zue mab) for AV-299, a potent, functional anti-HGF/c-MET antibody internally discovered at AVEO.

3 Feb 2011

Public health experts: Improved community engagement needed to prevent pandemic spread

In the current issue of Journal of Public Health Management and Practice, public health experts assert that improved community engagement is needed to prevent the spread of pandemics.

3 Feb 2011

Ta`am Teva Altman, Probi sign agreement to launch dietary supplement for gut health

Probi has signed an agreement giving Ta`am Teva Altman rights to launch Probi's dietary supplement for gut health based on Lp299v™ in Israel. The launch is planned to take place in the second quarter of 2011.

3 Feb 2011

Losartan improves effectiveness of nanotherapeutics against cancer

Low doses of an inexpensive, FDA-approved hypertension medication may improve the results of nanotherapeutic approaches to cancer treatment. In a report in the early edition of Proceedings of the National Academy of Sciences, Massachusetts General Hospital (MGH) investigators describe experiments showing that the generic drug losartan, by modifying the network of collagen fibers that characterizes most solid tumors, improved the effectiveness of two nanotherapeutics against several types of cancer.

3 Feb 2011

New study highlights black box warning inconsistencies on drug's label

A new study highlights inconsistencies in black box warnings - medication-related safety warnings on a drug's label - and argues for a more transparent and systematic approach to ensure these warnings are consistent across all drugs within a same category, and any additions to warnings, on the back of a drug withdrawal for example, are done within a reasonable and uniform time period.

3 Feb 2011

FDA disallows obesity drug Contrave pending further large-scale testing

In its latest blow to obesity medication development efforts, the US Food and Drug Administration (FDA) yesterday notified Orexigen Therapeutics that it would need to conduct an extremely large-scale study of the long-term cardiovascular effects of its drug, Contrave, before approval could be considered.

3 Feb 2011

Proper diagnosis and antibiotic treatment are the best way to prevent Lyme arthritis

Early, correct diagnosis is the best way to prevent the development of Lyme arthritis in individuals with the tick-borne illness, according to a paper published in the Journal of the American Academy of Orthopaedic Surgeons. In patients who do develop the condition, most cases can be treated successfully with antibiotics, the review found.

3 Feb 2011

Largazole appears to be an ideal blueprint for developing new drugs against bone diseases

One of Mother Nature's latest gifts to medical science is stirring excitement with the discovery that the substance - obtained from a coral-reef inhabiting cyanobacterium - appears to be an ideal blueprint for developing new drugs for serious fractures, osteoporosis, and other bone diseases.

3 Feb 2011

LSU biochemists develop 5-LOX 3-D model to design effective asthma medication

Chronic inflammation has been directly associated with heart disease and other physical ailments. But LSU graduate student Nathanial Gilbert and Professor of Biological Sciences Marcia Newcomer, together with Associate Professor Sue Bartlett, have developed the first 3-D model of Human 5-Lipoxygenase, or 5-LOX, the molecule responsible for creating inflammatory compounds that provoke asthma.

3 Feb 2011

Malarial drugs may help treat specific form of frontotemporal dementia

Frontotemporal dementia is caused by a breakdown of nerve cells in the frontal and temporal region of the brain, which leads to, among other symptoms, a change in personality and behavior. The cause of some forms of frontotemporal dementia is a genetically determined reduction of a hormone-like growth factor, progranulin.

3 Feb 2011

Researchers discover potential vaccine capable of reducing H. pylori colonization

A new study led by researchers at Rhode Island Hospital in collaboration with the University of Rhode Island and EpiVax. Inc, a privately owned vaccine development company in Providence, RI, has identified a potential vaccine capable of reducing colonization of Helicobacter pylori -- a known cause of gastritis, ulcer disease and cancer.

2 Feb 2011

Shire announces Health Canada's approval of VYVANSE for treatment of ADHD in adolescents and adults

Shire plc, the global specialty biopharmaceutical company, announces that Health Canada has approved VYVANSE® (lisdexamfetamine dimesylate capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adolescents and adults.

2 Feb 2011

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

Harbor BioSciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced publication of newly discovered anti-inflammatory steroids naturally present in humans.

2 Feb 2011

New research: Antioxidants in pecans may prevent development of various diseases

A new research study from Loma Linda University demonstrates that naturally occurring antioxidants in pecans may help contribute to heart health and disease prevention; the results are published in the January 2011 issue of The Journal of Nutrition.

2 Feb 2011

FDA issues reminder about safe use of non-sterile alcohol prep pads

Following a recent recall of potentially contaminated non-sterile alcohol prep pads, the U.S. Food and Drug Administration today reminded health care professionals about the safe use of non-sterile alcohol prep pads to clean and disinfect the surface of the skin.

2 Feb 2011

Skinvisible, Novartis enter agreement for technical feasibility study

Skinvisible Pharmaceuticals, has entered into a feasibility agreement with Novartis Pharma AG. Under the agreement Skinvisible will assess the technical feasibility of a topical formulation with an undisclosed compound utilizing its proprietary Invisicare polymer delivery system.

2 Feb 2011

Swine flu shots linked to narcolepsy: Investigation continues

The vaccine used against swine flu has been linked to a disorder called narcolepsy among those aged four to 19. Narcolepsy involves people falling asleep without warning or sleeping excessively in the daytime. A preliminary study also “observed [an] increase in incidence of narcolepsy” among those given the vaccine.

2 Feb 2011

Study finds treatment-related mortality with bevacizumab in cancer patients

Cancer patients treated with the chemotherapy agent bevacizumab may be at an increased risk of treatment-related death when the drug is used in combination with other therapies.

2 Feb 2011

Quebec provides access to new treatment for women with postmenopausal osteoporosis

Today Quebec is providing access to a therapy in a new class of osteoporosis treatments. With Quebec being the first province to list Prolia on public and private drug plans, Canadians living with osteoporosis in the province of Quebec now have access to increased treatment options.

2 Feb 2011

Pharmaceutical News

Genmab reports GBP 9 million net sales for Arzerra in fourth quarter 2010

AVEO receives USAN, WHO generic name approval for ficlatuzumab

Public health experts: Improved community engagement needed to prevent pandemic spread

Ta`am Teva Altman, Probi sign agreement to launch dietary supplement for gut health

Losartan improves effectiveness of nanotherapeutics against cancer

New study highlights black box warning inconsistencies on drug's label

FDA disallows obesity drug Contrave pending further large-scale testing

Proper diagnosis and antibiotic treatment are the best way to prevent Lyme arthritis

Largazole appears to be an ideal blueprint for developing new drugs against bone diseases

LSU biochemists develop 5-LOX 3-D model to design effective asthma medication

Malarial drugs may help treat specific form of frontotemporal dementia

Researchers discover potential vaccine capable of reducing H. pylori colonization

Shire announces Health Canada's approval of VYVANSE for treatment of ADHD in adolescents and adults

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

New research: Antioxidants in pecans may prevent development of various diseases

FDA issues reminder about safe use of non-sterile alcohol prep pads

Skinvisible, Novartis enter agreement for technical feasibility study

Swine flu shots linked to narcolepsy: Investigation continues

Study finds treatment-related mortality with bevacizumab in cancer patients

Quebec provides access to new treatment for women with postmenopausal osteoporosis

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News